OncoCyte Corp (NYSE:OCX) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research note issued on Thursday.

According to Zacks, “OncoCyte Corporation is primarily focused on the development of novel, non-invasive blood and urine diagnostic tests for detection of cancer. OncoCyte Corporation is based in Alameda, California. “

Several other equities analysts also recently weighed in on the stock. Benchmark Co. lifted their price target on shares of OncoCyte Corp from $7.50 to $8.00 and gave the company a “speculative buy” rating in a report on Tuesday, June 7th. Canaccord Genuity reaffirmed a “buy” rating on shares of OncoCyte Corp in a report on Wednesday, June 15th.

OncoCyte Corp (NYSE:OCX) opened at 3.98 on Thursday. OncoCyte Corp has a 12-month low of $2.45 and a 12-month high of $10.24. The company’s 50 day moving average is $3.97 and its 200 day moving average is $4.45. The company’s market cap is $101.22 million.

OncoCyte Corp (NYSE:OCX) last announced its earnings results on Thursday, August 11th. The company reported ($0.10) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.11) by $0.01. Analysts forecast that OncoCyte Corp will post $0.04 earnings per share for the current fiscal year.

About OncoCyte Corp

OncoCyte Corporation is a development-stage biotechnology company focused in the field of regenerative medicine. The Company is developing molecular cancer diagnostics utilizing a discovery platform that focuses on identifying genetic markers expressed in various types of cancer. It operates through the research and development of diagnostic tests for the detection of cancer segment.

5 Day Chart for NYSE:OCX

Get a free copy of the Zacks research report on OncoCyte Corp (OCX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for OncoCyte Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoCyte Corp and related companies with Analyst Ratings Network's FREE daily email newsletter.